Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MegaLT in Refractory Thrombocytopenia
NCT06534255Phase 1Completed
- Sponsor
- The First Affiliated Hospital of USTC
- Start
- Dec 2024
- Primary completion
- Jun 2025
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of MegaLT in Thrombocytopenia, sponsored by The First Affiliated Hospital of USTC. Primary endpoints: Adverse Events at 1 year, Incidence of bleeding events at 1 year and 3 more. Started Dec 2024; status: completed.
02
Drugs
MegaLT
03
Conditions
Thrombocytopenia
Beyond the preview
Go deeper on NCT06534255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06534255.